Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

INTRODUCTION: The safety of tofacitinib in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in clinical studies of ≤ 4 and 9.5 years, respectively. Post-marketing surveillance (PMS) data for tofacitinib from spontaneous and voluntary adverse event (AE) reports have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R., Coates, Laura C., Cohen, Stanley B., Tanaka, Yoshiya, Vranic, Ivana, Nagy, Edward, Lazariciu, Irina, Chen, All-shine, Kwok, Kenneth, Fallon, Lara, Kinch, Cassandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469130/
https://www.ncbi.nlm.nih.gov/pubmed/37458964
http://dx.doi.org/10.1007/s40744-023-00576-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469130/
https://www.ncbi.nlm.nih.gov/pubmed/37458964
http://dx.doi.org/10.1007/s40744-023-00576-8

Ejemplares similares